Excellent RAC-GS Updated 2022 Dumps With 100% Exam Passing Guarantee
Best way to practice test for RAPS RAC-GS
NEW QUESTION 23
A regulatory authority announces an inspection of a regulatory affairs professional's facility during a
holiday season when most of the staff Is not available. What is the MOST practical approach to this
dilemma?
- A. Insist that key personnel be available for the inspection.
- B. Inform the authority that the time is not suitable and request a new time
- C. Arrange for an inspection without all intended personnel.
- D. Negotiate with colleagues and the authority to find a better time.
Answer: D
NEW QUESTION 24
The manufacturer of an API was changed from Company X to Company Y during the late stage of a new
drug development. Despite differences in the manufacturing processes of the companies, both APIs meet
the current specifications. Which is the MOST appropriate information to include in the final submission
documents?
- A. The process information and analytical result of Company X API
- B. Information deemed appropriate by the regulatory authority
- C. The process information and analytical result of Company Y API
- D. The process information and the comparative analytical result of APIs from both companies
Answer: D
NEW QUESTION 25
A company is developing a new product for the global market. A new international guideline will
recommend relevant studies in the pediatric population, and the guideline will be effective before the
approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this
guideline on the successful registration of the new product?
- A. The company should consult with relevant regulatory authorities to determine the potential impact on
the current registration plan. - B. The new guideline has no impact on the current registration plan, but the company must be prepared to
defend its decision. - C. The new guideline has no impact on the current registration plan since all relevant registration studies
are almost completed. - D. The company should initiate the required pediatric studies immediately to avoid costly delays to the
current registration plan.
Answer: A
NEW QUESTION 26
After numerous failed attempts to decrease an identified risk in a medical device to an acceptable level,
the medical device continues to have unacceptable risks. However, the development team wants to
continue development. Which is the BEST recommendation to make in this situation?
- A. Perform another risk-benefit analysis.
- B. Redesign the device.
- C. Add a warning in the IFU.
- D. Discontinue the project.
Answer: B
NEW QUESTION 27
The regulatory authority in Country X issued a request for a mandatory product recall in Country X due to
serious injuries to patients. This product also is distributed in Country Y.
What should the regulatory affairs professional of the product's manufacturer FIRST do in Country Y?
- A. Initiate a mandatory recall of the product in Country Y.
- B. Review alt distribution records and complaints reported in Country Y.
- C. Draft a formal letter to customers in Country Y about this recall.
- D. Prepare the legal team in Country Y for possible litigations.
Answer: B
NEW QUESTION 28
Which term does NOT describe the same concept as the others?
- A. Follow-on protein products
- B. Monoclonal antibody
- C. Biosimilars
- D. Subsequent entry biologics
Answer: B
NEW QUESTION 29
During the review of a design dossier, the reviewer asks why the company has only carried out a
top-down risk approach. The reviewer is referring to which of the following?
- A. Fault tree analysis
- B. ISO 14971 risk analysis
- C. Hazard and operability study
- D. Failure mode and effect analysis
Answer: B
NEW QUESTION 30
Why is it necessary to run supplemental safety pharmacology studies?
- A. To provide adverse reaction reports and the results of the statistical data to the regulatory authority
- B. To evaluate potential adverse pharmacodynamics effects not addressed by the core battery
- C. To substitute the utilization of GLP
- D. To comply with regulatory authority requirements related to clinical studies
Answer: B
NEW QUESTION 31
A regulation change is imminent and may require further non-clinical testing on a product currently in
Phase III clinical trials. What is the most appropriate action to take FIRST?
- A. Consult with the company's legal department regarding options.
- B. Arrange for additional testing of the product at the testing facility.
- C. Obtain a copy of the proposed regulation and analyze the impact.
- D. Inform the company's senior management and arrange an emergency meeting
Answer: C
NEW QUESTION 32
The API used for an approved drug product conforms to international monograph specifications and local
pharmacopeia; however, the international monograph specifications of the API will be changing soon.
Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Confirm that the international monograph change is not related to local pharmacopeia.
- B. Prepare the international monograph change submission first and then prepare the local change when
required. - C. Analyze the impact of the international monograph change on the local pharmacopeia.
- D. Transfer the notice of the upcoming international monograph change to QA for further processing.
Answer: D
NEW QUESTION 33
According to ICH, which of the following components of study information is NOT required in a clinical
study report?
- A. List of lECs or lRBs
- B. Randomization scheme and codes
- C. Detailed CV of all investigators
- D. Protocol and protocol amendments
Answer: C
NEW QUESTION 34
During face-to-face meetings with the regulatory authority to address submission issues, what is the
BEST choice for the number of company representatives who should attend?
- A. As many as required by international standards
- B. As many as government attendees
- C. All senior management from the main office
- D. The minimum number of attendees necessary to address the issues
Answer: D
NEW QUESTION 35
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 4
- B. Module 2
- C. Module 3
- D. Module 1
Answer: B
NEW QUESTION 36
Under which of the following circumstances would a regulatory authority require a more detailed
premarket submission, a more rigorous audit, and/or the provision of more performance evaluation data
than would normally apply to an IVD device of that risk class?
- A. The device is an updated version of a compliant device from the same manufacturer and contains no
substantive change. - B. Internationally recognized standards are available to cover the main aspects of the device and have
been used by the manufacturer. - C. The device incorporates well-established technology that is already present in the market.
- D. The manufacturer's experience level with the type of IVD medical device is limited.
Answer: D
NEW QUESTION 37
What are the MOST important elements that global regulatory agencies want to know before approving a
new product for sale in their countries?
- A. Safety and failure risk
- B. Quality and failure risk
- C. Quality and effectiveness
- D. Safety and effectiveness
Answer: D
NEW QUESTION 38
At a recent scientific meeting, Company Y had two booths:
. At one booth, Company Y provided brochures on a completed Phase II study.
. In an adjacent booth, Company Y's sales professionals were promoting one of Company Y's marketed
products.
A regulatory affairs-professional at Company X sends a letter to a counterpart at Company Y requesting
that Company Y stop this practice in the future and demanding a formal response to the letter. How
should the regulatory affairs professional at Company Y BEST respond?
- A. Acknowledge receipt of the letter in a written response but do nothing further.
- B. Inform the legal department of the letter and discuss how to respond.
- C. Inform Company X that it has no right to send such a letter and do nothing further.
- D. Inform the local regulatory authority of the letter and discuss how to respond.
Answer: B
NEW QUESTION 39
A process is ultimately validated to ensure which of the following?
- A. The process meets the regulatory requirements.
- B. The process consistently meets the desired Quantity standards
- C. The process meets the quality system requirements.
- D. The process consistently produces the desired results.
Answer: D
NEW QUESTION 40
The intermediate manufacturing process was changed during development of a pharmaceutical. The
change may impact the API specification. Which functional area is responsible for the final approval of the
change?
- A. Production
- B. Analytical
- C. Regulatory
- D. Quality
Answer: D
NEW QUESTION 41
A drug product presents degradation during the manufacturing process. In addition to the amount, what
information should be provided FIRST in order to use API overage?
- A. Justification
- B. Property
- C. Formulation
- D. Specification
Answer: A
NEW QUESTION 42
A company establishes a new medical device indication for its consumer disposable products. The
regulatory affairs professional is asked to give a 30-minute training session on these products to sales
representatives. Which of the following subjects is the MOST important to discuss?
- A. Labeling
- B. Safety-related reporting
- C. Regulatory application summary
- D. Risk management process
Answer: A
NEW QUESTION 43
A company's product was approved by a regulatory authority with the condition that further studies must
be completed prior to full approval of the product.
To minimize product-associated risk to patients during the period of conditional approval, what is the
LEAST effective way to achieve this goal?
- A. Educate patients and healthcare providers on how to use the product
- B. Promote off-label use to a carefully selected patient population.
- C. Delay product launch until required studies are completed.
- D. Label the product for use in appropriate populations.
Answer: B
NEW QUESTION 44
Which of the following is NOT required to be included in a marketing application?
- A. Administrative forms
- B. Final printed label
- C. Evidence of fee payment
- D. Quality, safety, and efficacy Information
Answer: C
NEW QUESTION 45
Which of the following BEST describes the content of the "Physical, Chemical, and Pharmaceutical
Properties and Formulation" section of an IB?
- A. A brief summary of relevant physical, chemical, and pharmaceutical properties: instructions for storage
and handling of the dosage form: and a description of the formulation - B. A detailed summary of the physical and chemical properties of the drug product with a signed expert
statement addressing the suitability and stability of the formulation for its intended use - C. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation
method of the finished product - D. A review of available data to support the determination of the chemical structure and physical attributes
of the drug substance plus batch analysis and stability data for the finished formulation
Answer: A
NEW QUESTION 46
Which of the following statements regarding export regulations for an approved product is CORRECT?
- A. The product must not be in accord with the specifications of the foreign purchaser.
- B. The product must not be labeled on the outside of the shipping package that it is intended for export.
- C. The product must not be in conflict with the laws of the country to which it is intended for export.
- D. The product must not be sold or offered for sale in domestic commerce.
Answer: C
NEW QUESTION 47
A company is preparing the submission package for a drug to be registered in international markets.
When preparing the legal documentation, which document MUST comply with the WHO
recommendations?
- A. Certificate of Free Sale
- B. Certificate of GMP
- C. Certificate of Pharmaceutical Product
- D. Certificate of Analysis for the finished product
Answer: C
NEW QUESTION 48
......
Regulatory Affairs Certification (RAC) Global Scope Certification Sample Questions and Practice Exam: https://www.actualcollection.com/RAC-GS-exam-questions.html